3.8

CiteScore

2.4

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 29 Issue 6
Oct.  2015
Turn off MathJax
Article Contents
Abstract
Related Articles
Irena Druce, Hussein Abujrad, Teik Chye Ooi. PCSK9 and triglyceride-rich lipoprotein metabolism[J]. The Journal of Biomedical Research, 2015, 29(6): 429-436. DOI: 10.7555/JBR.29.20150052
Citation: Irena Druce, Hussein Abujrad, Teik Chye Ooi. PCSK9 and triglyceride-rich lipoprotein metabolism[J]. The Journal of Biomedical Research, 2015, 29(6): 429-436. DOI: 10.7555/JBR.29.20150052
shu

PCSK9 and triglyceride-rich lipoprotein metabolism

  • 1.

    Clinical Research Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, University of Ottawa, Ottawa, Ontario K1H 8L6, Canada

  • 2.

    Chronic Disease Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario K1H 7W9, Canada

More Information
  • Received Date: March 29, 2015
    Abstract
  • Pro-protein convertase subtilisin-kexin 9 (PCSK9) is known to affect low-density lipoprotein (LDL) metabolism,but there are indications from several lines of research that it may also influence the metabolism of other lipoproteins, especially triglyceride-rich lipoproteins (TRL). This review summarizes the current data on this possible role of PCSK9. A link between PCSK9 and TRL has been suggested through the demonstration of (1) a correlation between plasma PCSK9 and triglyceride (TG) levels in health and disease, (2) a correlation between plasma PCSK9 and markers of carbohydrate metabolism, which is closely related to TG metabolism, (3) an effect of TG-lowering fibrate therapy on plasma PCSK9 levels, (4) an effect of PCSK9 on postprandial lipemia, (5) an effect of PCSK9 on adipose tissue biology, (6) an effect of PCSK9 on apolipoprotein B production from the liver and intestines, (7) an effect of PCSK9 on receptors other than low density lipoprotein receptor (LDLR) that are involved in TRL metabolism, and (8) an effect of anti-PCSK9 therapy on serum TG levels. The underlying mechanisms are unclear but starting to emerge.
    • FullText(HTML)
    • References (0)
    • Related Articles

  • Related Articles

    [1]Wenqu Li, Zhenlong Wang, Huizhi Qi, Chengjie Xia, Feixue Chen, Juan Xu, Lei Zhang, Xuemei Jia. The association between HPV infection and endometriosis: Risk and fertility outcomes[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.39.20250194
    [2]Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
    [3]Tao Chun'ai, Gan Yongxin, Su Weidong, Li Zhutian, Tang Xiaolan. Effectiveness of hospital disinfection and experience learnt from 11 years of surveillance[J]. The Journal of Biomedical Research, 2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
    [4]Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
    [5]Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
    [6]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [7]Fengzhen Wang, Mingwan Zhang, Dongsheng Zhang, Yuan Huang, Li Chen, Sunmin Jiang, Kun Shi, Rui Li. Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery[J]. The Journal of Biomedical Research, 2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
    [8]Christopher J. Danford, Zemin Yao, Z. Gordon Jiang. Non-alcoholic fatty liver disease: a narrative review of genetics[J]. The Journal of Biomedical Research, 2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045
    [9]Hong-mei Gu, Da-wei Zhang. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9[J]. The Journal of Biomedical Research, 2015, 29(5): 356-361. DOI: 10.7555/JBR.29.20150067
    [10]Joseph M. Miano. Myocardin in biology and disease[J]. The Journal of Biomedical Research, 2015, 29(1): 3-19. DOI: 10.7555/JBR. 29.20140151

  • Cited by

    Periodical cited type(15)

    1. Arsh H, Manoj Kumar F, Simran F, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Ann Med Surg (Lond), 2024, 86(2): 899-908. DOI:10.1097/MS9.0000000000001601
    2. Saputri FC, Azmi NU, Puteri MU, et al. High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study. Nutrients, 2023, 15(20): 4463. DOI:10.3390/nu15204463
    3. Ishikawa H, Nagashima R, Kuno Y, et al. Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice. Diabetes Metab Syndr Obes, 2023, 16: 2855-2864. DOI:10.2147/DMSO.S428190
    4. Chen PW, Tseng SY, Chang HY, et al. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. Int J Mol Sci, 2022, 23(17): 9768. DOI:10.3390/ijms23179768
    5. Ayoub C, Azar Y, Maddah D, et al. Low circulating PCSK9 levels in LPL homozygous children with chylomicronemia syndrome in a syrian refugee family in Lebanon. Front Genet, 2022, 13: 961028. DOI:10.3389/fgene.2022.961028
    6. Bouchard J, Malalgoda M, Storsley J, et al. Health Benefits of Cereal Grain- and Pulse-Derived Proteins. Molecules, 2022, 27(12): 3746. DOI:10.3390/molecules27123746
    7. Majeed ML, Ghafil FA, Fatima G, et al. Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J Clin Biochem, 2021, 36(1): 74-80. DOI:10.1007/s12291-019-00858-5
    8. Fedoryak O, Arama C, Diarra I, et al. Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children. Can J Infect Dis Med Microbiol, 2020, 2020: 9340480. DOI:10.1155/2020/9340480
    9. Drouin-Chartier JP, Tremblay AJ, Hogue JC, et al. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. J Lipid Res, 2018, 59(8): 1501-1509. DOI:10.1194/jlr.M086264
    10. Chan DC, Watts GF, Somaratne R, et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol, 2018, 38(7): 1644-1655. DOI:10.1161/ATVBAHA.118.310882
    11. Eroğlu Z, Tetik Vardarlı A, Düzgün Z, et al. Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. Anatol J Cardiol, 2018, 19(5): 334-340. DOI:10.14744/AnatolJCardiol.2018.86648
    12. Hedayat AF, Park KH, Kwon TG, et al. Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model. Transl Res, 2018, 192: 30-45. DOI:10.1016/j.trsl.2017.10.007
    13. Chen IC, Tseng WK, Li YH, et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget, 2017, 8(64): 108042-108053. DOI:10.18632/oncotarget.22448
    14. Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Exp Ther Med, 2017, 13(3): 810-814. DOI:10.3892/etm.2017.4055
    15. Yu Z, Huang T, Zheng Y, et al. PCSK9 variant, long-chain n-3 PUFAs, and risk of nonfatal myocardial infarction in Costa Rican Hispanics. Am J Clin Nutr, 2017, 105(5): 1198-1203. DOI:10.3945/ajcn.116.148106

    Other cited types(0)

Catalog

    Teik Chye Ooi
    • 2.

      Chronic Disease Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario K1H 7W9, Canada

    1. On this Site
    2. On Google Scholar
    3. On PubMed
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3792) PDF downloads (617) Cited by(15)
    Related

    ©2025 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return